

Press release

SANEMUS wins European VC investors for Exact Imaging Inc. (Toronto)

Toronto/Munich, January 17th 2017. Exact Imaging Inc. (Toronto), a Canadian Medtech Start-Up, successfully closed its Series C Financing Round on December 22nd 2016 at the amount of CAD 21.5 Mio. (15.4 Mio. €). SANEMUS AG was in charge of finding the European investors.

With Vesalius Biocapital (Luxembourg) as European lead investor and PMV (Brussels) as European co-investor SANEMUS AG was able to attract two important investors for Exact Imaging Inc. The syndicate was rounded off with Lumira Capital (Toronto) as Canadian lead investor as well as iGan Partners/Rowanwood Ventures (Toronto) and the current investors as further co-investors.

Randy AuCoin, President & CEO der Exact Imaging Inc., about the collaboration with SANEMUS AG: 'Your professionalism, sense of urgency and quick understanding of our value proposition all served us well to help in the securing of the key partners and investors.'

About Exact Imaging Inc.

Exact Imaging has developed the micro-ultrasound system ExactVu™ to detect prostate cancer with a 300 times higher resolution than conventional ultrasound systems. Using ExactVu™, urologists will be able to visualize critical areas of interest in the prostate more precisely and specifically target biopsies at those areas. The ExactVu™ micro-ultrasound system has recently been granted regulatory approval in the European Union (CE Mark) and the United States (FDA 510(k)). The company will initiate its commercialization of ExactVu™ both in Europe and North America in the first half of 2017.

About SANEMUS AG

SANEMUS AG focuses on investing in the German healthcare market and offers strategic, financial and merger&acquisition advisory in this context. The investment focus is exclusively put on the Life Science sector with its submarkets pharmaceutical industry, biotechnology, medical technology, diagnostics and E-health.

SANEMUS AG
INVESTING IN HEALTH

Vorsitzender des Aufsichtsrats:
Dr. Jörg Weigell

Vorstand:
Dipl.-Kfm., Dipl.-Psych. Michael Thiess

Frauenstraße 12
80469 München

Tel: + 49 (0)89 1 89 44 89-0
Fax: + 49 (0)89 1 89 44 89-39

www.sanemus.com
info@sanemus.com

Merck Finck & Co.
München

IBAN: DE 90 7003 0400 0000 370 398
SWIFT Code MEFIDEMM

HRB München 16 20 43
Ust.-Id Nr.: DE 248 168 367
Steuer-Nr. 143/101/60157

Sitz der Gesellschaft:
München

Contact Person:

Sonja Terszowski, M. Sc.

Business Analyst

SANEMUS AG

Frauenstr. 12, 80469 München

Tel: +49 (0)89-189448918

sonja.terszowski@sanemus.com